si- RRM1 , 0.7 10 5
10.1016/j.molmet.2019.09.010 100 MllerT
Disclosures: Catherine Mezzacappa: Nothing to Disclose, Pedro Ochoa-Allemant: Nothing to Disclose, Marina Serper: Transplant Genomics: Grant/Research Support, Grifols: Grant/Research Support, Eurofins: Grant/Research Support, Tamar Taddei: Nothing to Disclose, Binu John: Exact Sciences: Grant/Research Support, Genentech: Grant/Research Support, Glycotest, Inc: Grant/Research Support, Gilead: Grant/Research Support, Exelixis: Consultant, Takeda: Grant/Research Support, GlaxoSmithKline: Consultant, Astra Zeneca: Consultant, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Nadim Mahmud: Nothing to Disclose 1081 THYROID DISORDERS (HYPOTHYRODISM AND HYPERTHYRODISM) AND THEIR ASSOCIATIONS WITH NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS: A STUDY ON INPATIENT OUTCOMES, INCIDENCE AND PREVALENCE Anwar Uddin Madia Ahad 1 Rafat Uddin 1 Selome Yewedalsew 1 Prashil Dave 1 Dipsa Shastri 2 Afgal Ahad 1 Rahat Uddin 1 Peter Lymberopoulos 1 Nazeera Ghanie 1 Sahil Chaddha 3 , 1 State University of New York Downstate, 2 East Tennessee State University, 3 SUNY Downstate Medical Center Background: Thyroid disorders are one of most common comorbid conditions present in patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
These statements have not been evaluated by the Food and Drug Administration (FDA)
